Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: Glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients

Diabetes, Obesity and Metabolism

Volumn 10, Issue 12, 2008, Pages 1261-1265

  Masuda, H ^a,b   Sakamoto, M ^a,b   Irie, J ^a,c   Kitaoka, A ^a,b   Shiono, K ^b   Inoue, G ^a,b   Atsuda, K ^b   Yamada, Satoru ^a,c  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Insulin lispro; Insulin therapy; Quality of life; Type 2 diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY MASS; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 55449093897     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00897.x     Document Type: Article

References (18)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828.
3. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: Overview of 6 years'therapy of type 2 Aiabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
4. Hirsch IB, Bergenstal RM, Parkin CP et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
5. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevent the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
6. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
7. Ishii H, Yamamoto T, Ohashi Y. Quality of lie in insulin users measured by ITR-QOL. J Japan Diab Soc 2001; 44: 17-22 (in Japanese).
8. Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: A prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004; 64: 19-25.
9. Yamada S, Watanabe M, Kitaoka A et al. Switching from premixed human insulin to premixed insulin lispro: A prospective study comparing the effects on glucose control and quality of life. Intern Med 2007; 46: 1513-1517.
10. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy; efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
11. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
12. McMahon GT, Dluhy RG. Intention to treat; initiating insulin and the 4-T study. N Engl J Med 2007; 357: 1759-1761.
13. Dungan KM, Buse JB, Largay J et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-1219.
14. The DECODE Study Group on behalf of the Europe an Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
15. Tominaga M, Egchi H, Manaka H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.
16. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23: B21-B29.
17. Kobayashi M, Yamazaki K, Hirao K et al. The status of diabetes control and antidiabetic drug therapy in Japan: A cross sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006; 73: 198-204.
18. Guttmann-Bauman I, Flaherty BP, Strugger M, McEvoy RC. Metabolic control and quality-of-life self-assessment in adolescents with IDDM. Diabetes Care 1998; 21: 915-918.